Conditions and diseases
Register as a stakeholder
NICE recommends that a national registry is developed to collect data on the use of the RD-100i OSNA system in detecting sent...
NICE recommends that studies directly comparing different epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation...
Current evidence on the safety and efficacy of irreversible electroporation for treating liver metastases is inadequate in qu...
Chemosaturation via percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic liver cancer (...
Further research designed to investigate differences in health-related quality of life and the clinical effectiveness of beva...
Studies exploring the effectiveness of bevacizumab in people previously treated with a taxane and its effects on health-relat...
Research on second-line treatments for transitional cell carcinoma of the urothelial tract is needed. It noted that the vinfl...
NICE recognised the importance of further clinical trials comparing the effectiveness of the tyrosine kinase inhibitors (afat...
NICE supports the manufacturer's ongoing commitment to collect data on the effectiveness of enzalutamide after previous treat...
NICE considered that if enzalutamide is used in routine clinical practice for treating hormone relapsed metastatic prostate c...
Use of Clinical Audit to improve a musculoskeletal (MSK) pathway: NICE Metastatic Spinal Cord Compression (MSCC) Guidelines